BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22495167)

  • 21. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes.
    Wiviott SD; de Lemos JA; Morrow DA
    Clin Chim Acta; 2004 Aug; 346(2):119-28. PubMed ID: 15256312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updating the role of natriuretic peptide levels in cardiovascular disease.
    Gopal DJ; Iqbal MN; Maisel A
    Postgrad Med; 2011 Nov; 123(6):102-13. PubMed ID: 22104459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum biomarkers for heart failure.
    Jarolim P
    Cardiovasc Pathol; 2006; 15(3):144-9. PubMed ID: 16697927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure.
    Morello AM; Januzzi JL
    Expert Rev Mol Diagn; 2006 Sep; 6(5):649-62. PubMed ID: 17009901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pro-B-type natriuretic peptide levels in acute decompensated heart failure.
    Waldo SW; Beede J; Isakson S; Villard-Saussine S; Fareh J; Clopton P; Fitzgerald RL; Maisel AS
    J Am Coll Cardiol; 2008 May; 51(19):1874-82. PubMed ID: 18466803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study.
    Boldanova T; Noveanu M; Breidthardt T; Potocki M; Reichlin T; Taegtmeyer A; Christ M; Laule K; Stelzig C; Mueller C
    Int J Cardiol; 2010 Jul; 142(3):265-72. PubMed ID: 19185372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State of the art: using natriuretic peptide levels in clinical practice.
    Maisel A; Mueller C; Adams K; Anker SD; Aspromonte N; Cleland JG; Cohen-Solal A; Dahlstrom U; DeMaria A; Di Somma S; Filippatos GS; Fonarow GC; Jourdain P; Komajda M; Liu PP; McDonagh T; McDonald K; Mebazaa A; Nieminen MS; Peacock WF; Tubaro M; Valle R; Vanderhyden M; Yancy CW; Zannad F; Braunwald E
    Eur J Heart Fail; 2008 Sep; 10(9):824-39. PubMed ID: 18760965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
    Maisel AS; Peacock WF; McMullin N; Jessie R; Fonarow GC; Wynne J; Mills RM
    J Am Coll Cardiol; 2008 Aug; 52(7):534-40. PubMed ID: 18687247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain natriuretic peptide in heart failure and beyond.
    Mowla MM; Bustami BB
    Saudi Med J; 2006 Oct; 27(10):1457-61. PubMed ID: 17013463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of brain natriuretic peptide (BNP) in the diagnosis and treatment of heart failure].
    Martin-Du Pan RC; Ricou F
    Rev Med Suisse Romande; 2003 Feb; 123(2):125-8. PubMed ID: 15095695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Natriuretic peptides--new diagnostic markers in heart disease].
    Angermann CE; Ertl G
    Herz; 2004 Sep; 29(6):609-17. PubMed ID: 15912436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
    Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
    J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?
    Rodeheffer RJ
    J Am Coll Cardiol; 2004 Aug; 44(4):740-9. PubMed ID: 15312852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain natriuretic peptide and optimal management of heart failure.
    Li N; Wang JA
    J Zhejiang Univ Sci B; 2005 Sep; 6(9):877-84. PubMed ID: 16130189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.
    Wu AH
    Am Heart J; 2006 Nov; 152(5):828-34. PubMed ID: 17070141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure.
    van Kimmenade RR; Pinto YM; Bayes-Genis A; Lainchbury JG; Richards AM; Januzzi JL
    Am J Cardiol; 2006 Aug; 98(3):386-90. PubMed ID: 16860029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
    Yamaji M; Tsutamoto T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Circ Heart Fail; 2009 Nov; 2(6):608-15. PubMed ID: 19919986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.